...IV protocol. One can assume that in anticipation of positive results from Second RPL (commencing May4th) that company is formulating the product for IV dispensing in preparation for Human Trials.
Likely with Positive RBL results = human trials will be set up in very short order.
Dr. Gottlieb interviewed on CNBC at 7:15pm said of Remdesivir ..."it could help certain patients at risk if administered very early on in the emergency room"...but "it is a "first gen" therapeutic, which is only the beginning and they are generally developed upon or replaced by other drugs" ... "it is far from a panacea" drug... (in other words...it's better than nothing right now)
Don't forget respiratory - COPD and Asthma is a $70B/yr market.
Also, I remember one of our main doctors in years past saying that the main grouping of current indications barely scratches the surface of expected/possible uses for Brilacidin.